¶ Sleep and Neurodegeneration
Sleep And Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes [1].
Sleep disturbances and circadian rhythm disruption are increasingly recognized as both early biomarkers and active contributors to the pathogenesis of neurodegenerative diseases. The relationship between sleep and neurodegeneration is bidirectional: neurodegenerative pathology damages sleep-regulating circuits, while impaired sleep accelerates the accumulation of toxic [proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/proteins—including [amyloid-β], tau], and [α-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX--—through failure of clearance mechanisms such as the [glymphatic system[/entities/[glymphatic-system[/entities/[glymphatic-system[/entities/[glymphatic-system--TEMP--/entities)--FIX--. This mechanistic link has profound implications for understanding disease progression and developing preventive strategies for [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, and other neurodegenerative conditions 1(https://www.sciencedirect.com/science/article/abs/pii/S0306452225002684) [2]
.
A landmark 2026 study in Nature Communications demonstrated that glymphatic clearance during normal sleep increased morning plasma levels of AD biomarkers (reflecting successful brain-to-blood clearance), while sleep deprivation blocked this clearance pathway—providing direct evidence in humans for the sleep-dependent waste clearance hypothesis 2(https://www.nature.com/articles/s41467-026-68374-8) [3].
¶ Sleep Architecture and the Brain
Normal sleep consists of cycling stages organized in approximately 90-minute ultradian cycles:
- NREM Stage 1 (N1): Light sleep, transition from wakefulness
- NREM Stage 2 (N2): Sleep spindles and K-complexes; consolidation of motor learning
- NREM Stage 3 (N3/Slow-Wave Sleep): Deep sleep dominated by slow oscillations (0.5–4 Hz); critical for glymphatic clearance, memory consolidation, and synaptic homeostasis
- REM Sleep: Rapid eye movements, muscle atonia, vivid dreaming; important for emotional memory processing and brain plasticity
Sleep depth is homeostatically regulated: high slow-oscillation power at sleep onset decreases progressively until awakening. REM sleep pressure also accumulates with prolonged wakefulness 3(https://link.springer.com/article/10.1007/s00213-026-07004-z) [4].
Key sleep-wake regulatory systems affected in neurodegeneration include:
- Orexin/Hypocretin system (lateral hypothalamus): Promotes and stabilizes wakefulness. Loss of orexin [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- causes narcolepsy and is observed early in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- and [Lewy body dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia--TEMP--/diseases)--FIX-- 4(https://onlinelibrary.wiley.com/doi/10.1111/jne.70085)
- Ventrolateral preoptic nucleus (VLPO): GABAergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- that promote NREM sleep
- Suprachiasmatic nucleus (SCN): Master circadian pacemaker; degenerates in AD, disrupting rest-activity rhythms
- Melanin-concentrating hormone (MCH) [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- (hypothalamus): Promote REM sleep; affected in neurodegenerative diseases
- Locus coeruleus (LC): Noradrenergic wake-promoting center; one of the earliest regions affected by tau pathology] in AD
- Cholinergic basal forebrain ([nucleus basalis of Meynert): Critical for cortical activation during wakefulness and REM sleep; severely degenerated in AD
- [brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem--TEMP--/brain-regions)--FIX-- [raphe nuclei[/brain-regions/[raphe-nuclei[/brain-regions/[raphe-nuclei[/brain-regions/[raphe-nuclei--TEMP--/brain-regions)--FIX--: Serotonergic regulation of sleep; affected early in [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--
¶ The Glymphatic System and Sleep-Dependent Clearance
The [glymphatic system[/entities/[glymphatic-system[/entities/[glymphatic-system[/entities/[glymphatic-system--TEMP--/entities)--FIX-- is a macroscopic waste clearance pathway that uses perivascular channels and [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX---mediated convective flow to remove metabolic waste products from the brain parenchyma 5(https://www.science.org/doi/10.1126/science.abb8739):
- Cerebrospinal fluid (CSF) enters the brain along periarterial spaces
- CSF exchanges with interstitial fluid (ISF) through aquaporin-4 (AQP4) channels on astrocyte end-feet
- Solutes—including [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX--, tau, and α-synuclein—are carried by convective bulk flow into perivenous spaces
- Waste-laden fluid exits the brain to cervical lymphatics for clearance
Glymphatic clearance is profoundly sleep-dependent:
- Interstitial space expansion: During sleep, the interstitial space expands by approximately 60%, dramatically increasing the convective flow of CSF through the brain parenchyma 6(https://www.science.org/doi/10.1126/science.abb8739)
- [norepinephrine[/entities/[norepinephrine[/entities/[norepinephrine[/entities/[norepinephrine--TEMP--/entities)--FIX-- oscillations: During NREM sleep, low-frequency norepinephrine oscillations from the [locus coeruleus[/brain-regions/[locus-coeruleus[/brain-regions/[locus-coeruleus[/brain-regions/[locus-coeruleus--TEMP--/brain-regions)--FIX-- drive synchronized changes in cerebral blood volume, propelling CSF movement through brain tissue 7(https://www.cell.com/cell/abstract/S0092-8674(24)01343-6)
- Slow-wave activity: Slow oscillations during deep sleep create rhythmic pulsations that drive CSF-ISF exchange
- Sleep position: Lateral sleep position may enhance glymphatic clearance compared to supine or prone positions
- Anesthesia: Glymphatic function is enhanced under anesthesia, suggesting that the reduced neural activity state rather than circadian timing per se is critical
Progressive impairment of glymphatic clearance has been proposed as a "final common pathway" to dementia 8(https://www.science.org/doi/10.1126/science.abb8739):
- Aging: AQP4 depolarization from astrocyte end-feet reduces glymphatic efficiency by 80–90% in aged animals
- Cerebral amyloid angiopathy (CAA): Perivascular amyloid deposits physically obstruct drainage pathways
- Reactive astrogliosis: [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX---driven astrocyte changes impair AQP4 polarization
- Arterial stiffening: Reduced arterial pulsatility diminishes the motive force for perivascular flow
- Sleep disruption: Chronic sleep loss reduces glymphatic clearance, allowing toxic protein accumulation
Sleep disturbances are among the earliest and most common non-cognitive symptoms of [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, often preceding clinical diagnosis by years or decades 9(https://link.springer.com/article/10.1007/s11910-025-01451-5):
Early changes:
- Decreased slow-wave sleep quantity and quality
- Increased sleep fragmentation and daytime napping
- Circadian rhythm phase advance (early awakening)
- Reduced sleep spindle density during NREM sleep
Mechanisms:
- SCN degeneration: [Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX--(/proteins/tau and amyloid pathology in the suprachiasmatic nucleus disrupts circadian pacemaker function 10(https://pmc.ncbi.nlm.nih.gov/articles/PMC10000289/)
- Basal forebrain cholinergic loss: Impairs cortical activation during wakefulness and destabilizes sleep architecture
- [locus coeruleus[/brain-regions/[locus-coeruleus[/brain-regions/[locus-coeruleus[/brain-regions/[locus-coeruleus--TEMP--/brain-regions)--FIX-- degeneration: Braak stage I tau pathology affects noradrenergic sleep-wake regulation
- Orexin system dysregulation: Altered orexin signaling contributes to sleep-wake instability
Bidirectional relationship with [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- and tau:
- Sleep deprivation increases interstitial [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- levels by 25–30% in humans, measured by microdialysis
- Tau phosphorylation] follows a circadian rhythm influenced by body temperature and sleep; sleep deprivation increases CSF tau by 50% 11(https://www.cell.com/heliyon/fulltext/S2405-8440(24)04850-3)
- Chronic sleep disruption accelerates amyloid plaque deposition and tau propagation] in animal models
- Slow-wave sleep disruption specifically correlates with increased cortical [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- deposition on [amyloid PET[/entities/[amyloid-pet[/entities/[amyloid-pet[/entities/[amyloid-pet--TEMP--/entities)--FIX--
Sundowning: [Late[/diseases/[late[/diseases/[late[/diseases/[late--TEMP--/diseases)--FIX---day agitation and confusion in AD patients reflects circadian dysregulation combined with accumulated sleep debt and reduced melatonin secretion.
[Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- is associated with a distinctive pattern of sleep disturbances:
REM Sleep Behavior Disorder (RBD):
- Characterized by loss of normal REM atonia with dream enactment behaviors (punching, kicking, vocalizing)
- Affects 30–60% of PD patients; may precede motor symptoms by 10–15 years
- Isolated RBD converts to α-synucleinopathy (PD, [Lewy body dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia--TEMP--/diseases)--FIX--, or [MSA) in >80% of cases over 10+ years
- Caused by degeneration of brainstem REM-atonia circuits (sublaterodorsal nucleus, magnocellular reticular formation) 12(](https://www.ncbi.nlm.nih.gov/sites/books/NBK606111/)
- Represents the most powerful prodromal biomarker for α-[synucleinopathies[/mechanisms/[synucleinopathies[/mechanisms/[synucleinopathies[/mechanisms/[synucleinopathies--TEMP--/mechanisms)--FIX--
Other sleep disturbances in PD:
- Excessive daytime sleepiness (30–50% of patients)
- Insomnia with sleep fragmentation (60–90%)
- Restless legs syndrome (10–20%)
- Sleep-disordered breathing
- Nocturia-related sleep disruption
Pathophysiology:
- [dopamine[/entities/[dopamine[/entities/[dopamine[/entities/[dopamine--TEMP--/entities)--FIX-- neuron loss in [substantia nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra--TEMP--/brain-regions)--FIX-- destabilizes sleep architecture
- α-synuclein deposition in brainstem sleep centers (Braak stages 1–2)
- [locus coeruleus[/brain-regions/[locus-coeruleus[/brain-regions/[locus-coeruleus[/brain-regions/[locus-coeruleus--TEMP--/brain-regions)--FIX-- degeneration impairs noradrenergic arousal regulation
- Hypothalamic orexin neuron involvement in advanced disease
[FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX-- patients exhibit:
- Disrupted circadian rest-activity rhythms
- Increased total sleep time (hypersomnia) in behavioral variant FTD
- REM sleep abnormalities, particularly in FTD with [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- pathology
- Prominent circadian rhythm disruption correlating with frontal lobe atrophy
[Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX-- involves:
- Progressive circadian rhythm disruption due to SCN dysfunction
- Reduced slow-wave sleep and disrupted sleep architecture
- Delayed sleep-wake phase disorder
- Circadian gene expression alterations in striatal [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--
- [huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX-- aggregates may directly impair clock gene transcription
[ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- patients experience:
- Sleep-disordered breathing from respiratory muscle weakness
- REM-related hypoventilation as an early respiratory sign
- Sleep fragmentation from cramps, pain, and immobility
- Fatigue from chronic hypoxemia and disrupted sleep architecture
Sleep deprivation directly promotes pathological protein accumulation through multiple mechanisms 13(https://www.oaepublish.com/articles/and.2021.10):
- Impaired clearance: Reduced glymphatic flow during wakefulness allows [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX--, tau, and α-synuclein to accumulate
- Increased production: Neuronal activity during extended wakefulness increases [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- release at synapses
- Altered proteostasis: Sleep loss impairs the [ubiquitin-proteasome system[/cell-types/[ubiquitin-proteasome-system[/cell-types/[ubiquitin-proteasome-system[/cell-types/[ubiquitin-proteasome-system--TEMP--/cell-types)--FIX-- and [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX---lysosomal pathway
- Unfolded protein response: Sleep deprivation activates the [UPR[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress--TEMP--/mechanisms)--FIX-- and [endoplasmic reticulum stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress[/mechanisms/[endoplasmic-reticulum-stress--TEMP--/mechanisms)--FIX-- in [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--
Chronic sleep disruption triggers sustained [neuroinflammatory] responses:
-
[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--:
-
Short sleep duration (<6 hours) in midlife is associated with a 30% increased dementia risk
-
Sleep-disordered breathing (obstructive sleep apnea) increases AD risk by 1.5–2-fold
-
Insomnia is associated with increased risk of PD and AD
-
Shift work and [circadian disruption[/mechanisms/[circadian-disruption[/mechanisms/[circadian-disruption[/mechanisms/[circadian-disruption--TEMP--/mechanisms)--FIX-- may increase long-term neurodegeneration risk
Melatonin and melatonin receptor agonists:
- Address circadian rhythm disruption in AD and PD
- May reduce sundowning symptoms
- Some evidence for neuroprotective effects through antioxidant and anti-inflammatory actions
- Melatonin secretion by the pineal gland is reduced in AD patients, correlating with SCN degeneration 17(https://onlinelibrary.wiley.com/doi/10.1111/jne.70085)
Orexin receptor antagonists (DORAs):
- Suvorexant has shown improved sleep quality in AD patients
- May enhance glymphatic clearance by promoting deeper sleep
- Dual orexin receptor antagonists may reduce nocturnal [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- levels
- Under investigation for disease-modifying potential in AD
Trazodone:
- Commonly used for sleep disturbances in dementia
- May increase slow-wave sleep and potentially enhance glymphatic clearance
Clonazepam and melatonin for RBD:
- First-line [treatments[/[treatments[/[treatments[/[treatments[/[treatments[/[treatments[/[treatments[/treatments for REM sleep behavior disorder in PD/LBD
- May reduce injury from dream enactment behaviors
Light therapy:
- Morning bright light exposure can strengthen circadian rhythms
- May improve sleep-wake patterns and reduce sundowning in AD
- LED-based phototherapy showing promise in [clinical trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/clinical-trials
Sleep hygiene optimization:
- Consistent sleep-wake schedule
- Adequate sleep duration (7–8 hours for adults)
- Treatment of sleep-disordered breathing (CPAP for obstructive sleep apnea)
- Environmental modifications (temperature, noise, light control)
Exercise:
- Regular physical activity improves sleep quality and may enhance glymphatic clearance
- Aerobic exercise increases slow-wave sleep and improves circadian rhythm amplitude
- May have additive neuroprotective effects through [BDNF[/entities/[bdnf[/entities/[bdnf[/entities/[bdnf--TEMP--/entities)--FIX-- upregulation
Cognitive behavioral therapy for insomnia (CBT-I):
- Evidence-based first-line treatment for insomnia
- Effective in patients with [mild cognitive impairment[/diseases/[mci[/diseases/[mci[/diseases/[mci--TEMP--/diseases)--FIX--
- Preferable to pharmacological approaches due to fewer side effects
- Auditory stimulation: Phase-locked acoustic stimulation during NREM sleep to enhance slow oscillations and potentially increase glymphatic clearance
- Transcranial direct current stimulation (tDCS): Enhancement of slow-wave activity during sleep
- Glymphatic-targeted therapies: AQP4 modulators, arterial pulsation enhancers
- Chronotherapy: Time-restricted feeding and timed light exposure to strengthen circadian rhythms
- Sleep biomarkers: EEG-derived sleep quality metrics as early biomarkers for neurodegeneration risk
The study of Sleep And Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms and continues to drive therapeutic development [5].
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions [6].
- [Astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--
- [alpha-synuclein (α-Syn)[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX--
- [Huntingtin (HTT)[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX--
- ^1]: Ju YE, et al. Sleep and neurodegeneration: a systematic review. Neurology. 2014;83(8):721-728. DOI:10.1212/WNL.0000000000000688
- ^2]: Ju YS, et al. Sleep continuity and architecture in aging and [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--. Sleep Med Clin. 2015;10(2):xvii-xx. DOI:10.1016/j.jsmc.2015.02.003
- ^3]: Bokenberger K, et al. Sleep disturbances and risk of dementia. Neurology. 2015;84(11):1128-1137. DOI:10.1212/WNL.0000000000001315
- ^4]: Pase MP, et al. Sleep architecture and subsequent risk of dementia. Neurology. 2017;89(12):1244-1250. DOI:10.1212/WNL.0000000000004371
- ^5]: Nedergaard M, Goldman SA. Glymphatic failure as a final common pathway to dementia. Science. 2020;370(6512):50-56. DOI:10.1126/science.abb8739
- ^6]: Xie L, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373-377. DOI:10.1126/science.1241224
- ^7]: Holth J, et al. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science. 2019;363(6429):880-884. DOI:10.1126/science.aav2546
- ^8]: Iliff JJ, et al. Brain-wide glymphatic pathway for the clearance of interstitial waste. J Neurosci. 2013;33(44):18190-18199. DOI:10.1523/JNEUROSCI.3242-13.2013
- ^9]: Musiek ES, Holtzman DM. Sleep, circadian rhythms, and the pathogenesis of Alzheimer's Disease. Exp Mol Med. 2015;47(3):e148. DOI:10.1038/emm.2014.121
- ^10]: Kang JE, et al. [Amyloid[/entities/amyloid dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326([5955[/entities/amyloid dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326([5955[/entities/amyloid dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326([5955[/entities//entities/amyloid dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326([5955[/entities//entities//entities/amyloid dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326([5955[/entities//entities//entities//entities/amyloid dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326([5955[/entities//entities//entities//entities//entities/amyloid dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326([5955](/entities//entities//entities//entities//entities/amyloid dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326(5955) DOI:10.1126/science.1180962)
- [Zhang X, et al. (2025]. Exploring the nexus: Sleep disorders, circadian dysregulation, and [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--. Neuroscience. [ScienceDirect]https://www.sciencedirect.com/science/article/abs/pii/S0306452225002684)
- [Eide PK, et al. (2026]. The glymphatic system clears [Amyloid-Beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- and tau from brain to plasma in humans. Nature Communications. [Nature]https://www.nature.com/articles/s41467-026-68374-8)
- [Müller F, et al. (2026]. Glymphatic system dysfunction: a link between sleep disorders and neurodegeneration. Psychopharmacology. [Springer]https://link.springer.com/article/10.1007/s00213-026-07004-z)
- [Guillot SJ, et al. (2025]. Sleep in neurodegenerative diseases: A focus on melatonin, melanin-concentrating hormone and orexin. Journal of Neuroendocrinology. [Wiley]https://onlinelibrary.wiley.com/doi/10.1111/jne.70085)
- [Nedergaard M, Goldman SA. (2020]. Glymphatic failure as a final common pathway to dementia. Science, 370(6512), 50-56. [Science]https://www.science.org/doi/10.1126/science.abb8739)
- [Bojarskaite L, et al. (2024]. Norepinephrine-mediated slow vasomotion drives glymphatic clearance during sleep. Cell. [Cell]https://www.cell.com/cell/abstract/S0092-8674(24)
- [Wang Y, et al. (2025]. Sleep abnormalities and risk of [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--. Current Neurology and Neuroscience Reports. [Springer]https://link.springer.com/article/10.1007/s11910-025-01451-5)
- [Uddin MS, et al. (2023]. Circadian dysfunction and Alzheimer's Disease – An updated review. Ageing Research Reviews. PMC)
- [Chen L, et al. (2024]. Sleep deprivation: A risk factor for the pathogenesis and progression of Alzheimer's Disease. Heliyon. [Cell]https://www.cell.com/heliyon/fulltext/S2405-8440(24)
- [StatPearls. (2024]. Sleep and Neurodegenerative Disorders. NCBI Bookshelf. [NCBI]https://www.ncbi.nlm.nih.gov/sites/books/NBK606111/)
- [Wang Y, et al. (2021]. Influence of sleep disruption on protein accumulation in neurodegenerative diseases. Ageing and Neurodegenerative [Diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases. [OAE Publishing]https://www.oaepublish.com/articles/and.2021.10)
- [Zhang W, et al. (2025]. Circadian rhythm dysfunction in neurodegenerative diseases: A bidirectional perspective. Nature and Science of Sleep. [Dove Press]https://www.dovepress.com/circadian-rhythm-dysfunction-in-neurodegenerative-diseases-a-bidirecti-peer-reviewed-fulltext-article-NSS)
- [Zhao XS, et al. (2021]. Chronic sleep deprivation altered the expression of circadian clock [genes[/[genes[/[genes[/[genes[/[genes[/[genes[/[genes[/genes and aggravated Alzheimer's Disease neuropathology. Brain Research. PubMed)
- [Martinez-Gonzalez MA, et al. (2026]. Sleep disturbances and Alzheimer's Disease: a multiscale approach from exposome to neurobiology and [precision medicine[/treatments/[precision-medicine[/treatments/[precision-medicine[/treatments/[precision-medicine--TEMP--/treatments)--FIX--. GeroScience. [Springer]https://link.springer.com/article/10.1007/s11357-026-02152-8)
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
24 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
75% |
Overall Confidence: 51%